Physician profile
Cara Lye
NPI 1851649016
$575.63
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.86 · 2022: $134 · 2023: $136 · 2024: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $117.75 | 2022 | |
| Pfizer INC. | $94.19 | 2024 | |
| Ironshore Pharmaceuticals INC. | $62.57 | 2021-2024 | Jornay Pm |
| Mayne Pharma Commercial LLC | $39.22 | 2023 | |
| Sanofi Pasteur INC. | $33.59 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $32.63 | 2021-2023 | Proquad, Varivax, Gardasil 9 |
| Verrica Pharmaceuticals INC. | $27.24 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $26.21 | 2024 | Shingrix |
| Lilly USA, LLC | $24.30 | 2024 | Zepbound |
| Foundation Fusion Solutions, LLC | $21.77 | 2021 | |
| Cranial Technologies, INC | $20.32 | 2023 | Doc Band |
| Irhythm Technologies, INC. | $20.30 | 2024 | Zio Xt Patch |
| Tris Pharma INC | $14.28 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2021 | |
| Sobi, INC | $13.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.69 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Lye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.